VYGR - ボイジャ―・セラピュ―ティクス (Voyager Therapeutics Inc.) ボイジャ―・セラピュ―ティクス



symbol VYGR
会社名 Voyager Therapeutics Inc (ボイジャ―・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 ボイジャー・セラピューティクス(Voyager Therapeutics Inc.)は臨床段階の遺伝子治療会社である。同社は中枢神経系(CNS)疾患患者向け治療法の開発を行う。同社のパイプラインは進行性パーキンソン病、筋萎縮性側索硬化症(ALS)の単一遺伝子病、ハンチントン病、フリードライヒの運動失調、前頭側頭型認知症・アルツハイマー病及び慢性疼痛を含むCNS適応症向けプログラムを含む。同社の臨床的製品候補であるVY-AADC01は進行性パーキンソン病の治療向けアデノ随伴ウイルス(AAV)遺伝子治療薬候補である。VY-AADC01は複数のAAV遺伝子治療臨床試験に使用されるAAV2キャプシドと芳香族L-アミノ酸デカルボキシラーゼ(AADC)トランスジーンの発現を駆動するサイトメガロウイルスプロモーターを含む。パイプラインにはVY-SOD101、VY-FXN01、VY-HTT01、VY-TAU01、VY-NAV01を含む。   ボイジャ―・セラピュ―ティクスは米国のバイオ医薬品企業。臨床段階で、中枢神経系の疾患に対する遺伝子治療の開発に従事。特定のタンパク質に焦点を当て、アデノ随伴ウイルス遺伝子治療のアプロ―チにより症状の進行を遅らせることを目的とする。主にパ―キンソン病、脊髄筋萎縮症、ハンチントン舞踏病などの治療に貢献する。本社はマサチュ―セッツ州ケンブリッジ。   Voyager Therapeutics is a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases. Voyager is committed to advancing the field of AAV gene therapy through innovation and investment in vector engineering and optimization, manufacturing, and dosing and delivery techniques. Voyager's wholly owned and partnered pipeline focuses on severe neurological diseases for which effective new therapies are needed, including Parkinson's disease, Huntington's disease, Friedreich's ataxia, and other severe neurological diseases.
本社所在地 75 Sidney Street Cambridge MA 02139 USA
代表者氏名 Mark J. Levin マーク・J.レヴィン
代表者役職名 Independent Chairman of the Board
電話番号 +1 857-259-5340
設立年月日 41426
市場名 NASDAQ National Market System
ipoyear 2015年
従業員数 89人
url www.voyagertherapeutics.com
nasdaq_url https://www.nasdaq.com/symbol/vygr
EBITDA EBITDA(百万ドル) -80.64900
終値(lastsale) 16.96
時価総額(marketcap) 550114712.64
時価総額 時価総額(百万ドル) 509.24530
売上高 売上高(百万ドル) 11.01000
企業価値(EV) 企業価値(EV)(百万ドル) 313.12230
当期純利益 当期純利益(百万ドル) -80.64200
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Voyager Therapeutics Inc revenues increased 33% to $3.5M. Net loss increased 28% to $45.5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Stock-based Compensation in SGA increase from $1.8M to $7.9M (expense) General and administrative increase of 45% to $11M (expense).



   Voyager Therapeutics to Participate in Upcoming Investor Conferences  2023/02/09 12:00:00 GlobeNewswire
CAMBRIDGE, Mass., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced that management will participate in the following investor conferences:
   Voyager Therapeutics Inc. (VYGR) produces promising results  2023/02/01 12:48:00 US Post News
In Tuesday’s session, Voyager Therapeutics Inc. (NASDAQ:VYGR) marked $9.44 per share, up from $9.07 in the previous session. While Voyager Therapeutics Inc. has overperformed by 4.08%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, VYGR rose by 234.75%, with highs and lows ranging from $10.81 to […]
   7 A-Rated Stocks to Buy for Less Than $25  2023/01/24 11:15:09 InvestorPlace
The overall stock market may be demonstrating resilience, but as uncertainty continues to run high, stocks have only made a modest, partial recovery. However, this works to your advantage, as many stocks remain at low prices, including the best stocks to buy for less than $25 per share. Although investors are starting to wager on a 2023 pivot on interest rates by the Federal Reserve , inflation remains at multi-decade highs. The Fed could still decide to keep raising rates until inflation starts to ease. With this, there may be a round or two of additional volatility before the bull market returns. Yet if you focus on high-quality lower-priced stocks, this isn’t a major concern. These names can handle additional volatility. Some of these could perform strongly with secular growth catalysts even if the overall stock market stays in a slump throughout the year. So, what are the best stocks to buy for less than $25 per share? Consider these seven. Each one earns an A rating in Portfolio Grader.
   Why Voyager Therapeutics Stock Is Sinking This Week  2023/01/20 17:08:38 The Motley Fool
Investors are taking profits on this red-hot stock this week.
   Voyager Stock: Neurocrine Deal Signals More Upside (NASDAQ:VYGR)  2023/01/14 09:19:17 Seeking Alpha
In trying to deliver breakthrough, Voyager is able to ink multiple robust deals with reputable companies. Read why the Neurocrine deal signals more upside for VYGR.
   Voyager Therapeutics, Inc. (VYGR) Q3 2022 Earnings Call Transcript  2022/11/08 17:22:05 Seeking Alpha
Voyager Therapeutics, Inc. (NASDAQ:NASDAQ:VYGR) Q3 2022 Results Conference Call November 08, 2022 08:30 AM ET Company Participants Alfred Sandrock - Chief Executive Officer Peter…
   Voyager Therapeutics GAAP EPS of $0.45 beats by $0.79, revenue of $41.1M beats by $32.07M  2022/11/08 12:08:10 Seeking Alpha
Voyager Therapeutics press release (VYGR): Q3 GAAP EPS of $0.45 beats by $0.79.Revenue of $41.1M (+2677.0% Y/Y) beats by $32.07M.Cash, cash equivalents and marketable securities as…
   Voyager Therapeutics Reports Third Quarter 2022 Financial and Operating Results  2022/11/08 12:00:00 GlobeNewswire
- Voyager’s TRACER TM capsid platform validated by Pfizer option exercise -
   Voyager Therapeutics, Inc.: Voyager Therapeutics Reports Third Quarter 2022 Financial and Operating Results  2022/11/08 12:00:00 Finanz Nachrichten
- Voyager''s TRACERTM capsid platform validated by Pfizer option exercise - - Data characterizing a novel receptor and demonstrating low-dose potential further validate TRACER - - Pipeline programs…
   Voyager Therapeutics Q3 2022 Earnings Preview  2022/11/07 18:03:37 Seeking Alpha
Voyager Therapeutics (VYGR) is scheduled to announce Q3 earnings results on Tuesday, November 8th, before market open.The consensus EPS Estimate is -$0.43 (+35.8% Y/Y) and the…
   Analysts Predict A Surge In Voyager Therapeutics Inc. (NASDAQ: VYGR)?  2022/06/25 16:00:00 Stocks Register
Voyager Therapeutics Inc. (NASDAQ:VYGR) shares, rose in value on Friday, 06/24/22, with the stock price down by -1.37% to the previous day’s close as strong demand from buyers drove the stock to $5.76. Actively observing the price movement in the last trading, the stock closed the session at $5.84, falling within a range of $5.66 … Analysts Predict A Surge In Voyager Therapeutics Inc. (NASDAQ: VYGR)? Read More »
   Voyager Therapeutics Inc. (NASDAQ: VYGR) Has Advanced 11.36% In 2022; Is The Share Price Attractive Enough At $10.00?  2022/06/18 14:00:00 Marketing Sentinel
Voyager Therapeutics Inc. (NASDAQ:VYGR)’s traded shares stood at 0.17 million during the last session, with the company’s beta value hitting 1.12. At the close of trading, the stock’s price was $5.00, to imply an increase of 3.73% or $0.18 in intraday trading. The VYGR share’s 52-week high remains $10.60, putting it -112.0% down since that … Voyager Therapeutics Inc. (NASDAQ: VYGR) Has Advanced 11.36% In 2022; Is The Share Price Attractive Enough At $10.00? Read More »
   Voyager Therapeutics Inc. (NASDAQ:VYGR) Stock Boosted 99.26% So Far In 2022, What Analysts Expect Next?  2022/06/11 15:00:00 Marketing Sentinel
In last trading session, Voyager Therapeutics Inc. (NASDAQ:VYGR) saw 0.44 million shares changing hands with its beta currently measuring 1.10. Company’s recent per share price level of $5.40 trading at -$0.03 or -0.55% at ring of the bell on the day assigns it a market valuation of $197.05M. That closing price of VYGR’s stock is … Voyager Therapeutics Inc. (NASDAQ:VYGR) Stock Boosted 99.26% So Far In 2022, What Analysts Expect Next? Read More »
   Looking Back In On Voyager Therapeutics  2022/06/08 21:55:55 Seeking Alpha
Voyager Therapeutics has signed licensing deals with two large drug makers since we last looked in on it. Read what to know about VYGR stock here.
   Pharmaceutical Drug Development Sector Scorecard 2022: High-Value Deals Continue to Drive the Immuno-oncology and Genomics Markets But Several Companies Sell Biosimilar Portfolios - ResearchAndMarkets.com  2022/06/07 09:03:00 Kwhen Finance

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ボイジャ―・セラピュ―ティクス VYGR Voyager Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)